← Back to all trials
Active Not Recruiting
NCT06489041
Evaluating Microarray Pharmacogenetic Testing in Cancer Patients
Conditions: Cancer, Gastrointestinal Cancer
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 120
Sponsor: Wake Forest University Health Sciences
Location: Atrium Health Levine Cancer Charlotte North Carolina
Summary
The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.
Eligibility Criteria
Inclusion Criteria:
* Written informed consent and HIPAA authorization for release of personal health information.
* Age ≥ 18 years at the time of consent.
* Eligible for standard of care single-gene DPYD testing (i.e., receiving or expected to receive a fluoropyrimidine-based chemotherapy regimen). The potential participant meets inclusion criteria if the standard of care single-gene DPYD test is planned or previously ordered. If previously ordered, consent must occur no later than 60 days from the date the DPYD results were available.
* Willing to provide additional buccal swabs if residual DNA from previous DPYD testing is inadequate for microarray testing.
Exclusion Criteria:
• History of prior allogeneic hematopoietic cell transplantation or liver transplantation
Source: ClinicalTrials.gov (NCT06489041). StuddyBuddy aggregates publicly available trial information.
